KEAP1 and non-small cell lung carcinoma: Two well-known alterations associated with poor immunotherapy outcomes in NSCLC are STK11 gene inactivation and KEAP1 depletion, which are associated with epigenetic inhibition of STING important to the T cell activation pathway and reduced leukocyte infiltration with differential immune cell recruitment, respectively[74,75].